Quarterly report pursuant to Section 13 or 15(d)

CONCENTRATIONS

v3.5.0.2
CONCENTRATIONS
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Note 15 - CONCENTRATIONS

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

 

The Company's revenues earned from sale of products and services for the three months ended September 30, 2016 included 13%, 34%, 24% and 26% (aggregate of 97%) from four customers of the Company's total revenues.

 

The Company's revenues earned from sale of products and services for the nine months ended September 30, 2016 included 14% and 17% (aggregate of 31%) from two customers of the Company's total revenues.

 

The Company's revenues earned from sale of products and services for the three months ended September 30, 2015 included 21%, 10%, 29%, 10%, 10% and 10% (aggregate of 90%) from six customers of the Company's total revenues. 

 

The Company's revenues earned from sale of products and services for the nine months ended September 30, 2015 included 14%, 24%, 10% and 16% (aggregate of 64%) from four customers of the Company's total revenues. 

 

Three customers accounted for 27%, 11% and 18% (aggregate of 56%) of the Company's total accounts receivable at September 30, 2016 and two customers accounted for 49% and 20% of the Company's total accounts receivable at December 31, 2015.

 

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.